Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31263588 | 1.00 | GSK3A (0.49) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL30718706 | 0.92 | CYP2A6 (0.46) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL933672 | 0.92 | CYP2A6 (0.46) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL20951048 | 0.77 | ALDH1A1 (0.36) | KDM4EALDH1A1GRM4SMN1; SMN2 | |
| SCHEMBL14684657 | 0.76 | MAP3K5 (0.42) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL19681405 | 0.75 | EGFR (0.46) | EGFRKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL15447404 | 0.75 | MAPT (0.43) | MEN1ALDH1A1KMT2AMAPTCYP1A2 | |
| SCHEMBL2671761 | 0.75 | GSK3A (0.45) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL6845001 | 0.75 | CYP2A6 (0.57) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL1519794 | 0.75 | GSK3A (0.45) | GSK3ACDK9CDK5TAOK1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113877483-B | Low-temperature continuous synthesis device and method for pharmaceutical intermediate halogenated isoquinoline boric acid | 烟台宁远药业有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-113877483-A | Low-temperature continuous synthesis device and method for pharmaceutical intermediate halogenated isoquinoline boric acid | 烟台宁远药业有限公司 | 2022-01-04 | — | — | CN | claimed |
| CN-108929270-B | Synthesis of drug intermediate disubstituted nitrogen heterocyclic ring-containing amine compound | 上海罕道医药科技有限公司 | 2021-06-08 | — | — | CN | claimed |
| EP-4739683-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4727939-A1 | 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4688768-A1 | NOVEL METTL3 INHIBITORS AND USE THEREOF IN THERAPY | Novalix (FR) | 2026-02-11 | — | — | EP | disclosed |
| US-12448392-B2 | Spiropiperidine derivatives | CEPHALON LLC (US) | 2025-10-21 | — | — | US | disclosed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025046148-A1 | NOVEL PARG INHIBITORS | FORX THERAPEUTICS AG (CH) | 2025-03-06 | — | — | WO | disclosed |
| US-20130022573-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | SELCIA LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130022573-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | SELCIA LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2012078915-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078915-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | GSK3A 3415/4885CDK9 2428/4885CDK5 1979/4885 |
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | GSK3A 427/4885CDK9 46/4885CDK5 174/4885 |
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | STAT6, STAT3, STAT1 | GSK3A 3182/4885CDK9 326/4885CDK5 377/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | GSK3A 427/4885CDK9 46/4885CDK5 174/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | GSK3A 3416/4885CDK9 2347/4885CDK5 1806/4885 |
| US-12448392-B2 | Spiropiperidine derivatives | FASN, FADS2, SCD5 | GSK3A 2550/4885CDK9 3151/4885CDK5 2803/4885 |
| US-20130022573-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, CYP2F1 | GSK3A 3573/4885CDK9 1482/4885CDK5 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.